You are here
Articles
Posted on Monday, December 9, 2013 - 1:46pm
Results of study: Personalized Cellular Therapy CTL019
NEW ORLEANS — Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to...
Posted on Tuesday, December 3, 2013 - 11:08pm
254 Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months.
Posted on Friday, November 22, 2013 - 3:02pm
22/11/2013
European Medicines Agency recommends changes in use of leukaemia medicine Iclusig (ponatinib) in order to minimise risk of blood clots
The European Medicines Agency’s Committee for Medicinal...
Posted on Tuesday, November 19, 2013 - 6:32pm
David M. Ross1,*, Susan Branford2, John F. Seymour3, Anthony P. Schwarer4, Christopher Arthur5, David T. Yeung6, Phuong Dang1, Jarrad M. Goyne1, Cassandra Slader7, Robin J. Filshie8, Anthony K. Mills9, Junia V. Melo10,...
Posted on Tuesday, November 12, 2013 - 9:16am
08/11/2013
PRAC updates on the risks of serious vascular occlusive events associated with cancer medicine Iclusig
Modification of product information under way to include strengthened warnings
...
Posted on Monday, November 4, 2013 - 11:09am
A bone drug already on the market for osteoporosis may kill chronic myelogenous leukemia (CML) stem cells thought to persist in the bone marrow after standard therapy, lowering the likelihood of disease recurrence,...
Posted on Friday, November 1, 2013 - 10:16am
Silas Inman
Published Online: Thursday, October 31, 2013
Marketing and commercial distribution of ponatinib (Iclusig) has been temporarily suspended, following an ongoing FDA investigation that revealed an increased...
Posted on Friday, November 1, 2013 - 10:11am
This update is in follow-up to the FDA Drug Safety Communication: FDA investigating leukemia drug Iclusig (ponatinib) after increased reports of serious blood clots in arteries and veins issued on October 11, 2013.
Posted on Sunday, October 20, 2013 - 6:52pm
Josephs DH, Fisher DS, Spicer J, Flanagan RJ.
Posted on Friday, October 18, 2013 - 7:12pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 18, 2013-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia...
Posted on Thursday, October 17, 2013 - 12:21pm
Iclusig (Ponatinib): Drug Safety Communication - Increased Reports Of Serious Blood Clots In Arteries And Veins
[Posted 10/11/2013]
AUDIENCE: Health Professional, Oncology
ISSUE: FDA is investigating an increasing...
Posted on Thursday, October 10, 2013 - 10:23am
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig® (ponatinib) and actions that it is taking following consultations with...
Posted on Friday, September 27, 2013 - 12:36pm
Treatment of chronic myeloid leukemia (CML) has evolved considerably in recent years. Chemotherapy with hydroxyurea and busulfan were the main options for many years, and although these agents can control hematologic...
Posted on Wednesday, August 7, 2013 - 1:07pm
J E Kim1,7, S Yoon1,7, B-R Choi1, K P Kim2, Y-H Cho3, W Jung4, D-W Kim5, S Oh6 and D-E Kim1
The BCR–ABL fusion transcript encodes the BCR–ABL tyrosine kinase (TK), which causes chronic myelogenous leukemia (CML)....
Posted on Monday, July 29, 2013 - 2:34pm
Ahmad Hamad, Zeyad Sahli, Maya El Sabban, Maha Mouteirik, and Rihab Nasr
Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon
13...
- ‹ previous
- 13 of 33
- next ›